Abstract
Pathogenic variants in ATP13A2, which encodes an endolysosomal polyamine exporter, cause Kufor-Rakeb syndrome and are associated with early-onset parkinsonism and related neurodegenerative disorders, however, the mechanisms by which ATP13A2 dysfunction drives disease remain incompletely defined. In Atp13a2 knockout mice, we identified an early, transient reduction in brain polyamines that precedes overt gliosis and behavioural abnormalities. Pharmacological polyamine depletion exacerbates phenotypes, whereas oral supplementation of spermidine, but not spermine, rescues parkinsonian symptoms establishing metabolic polyamine deficiency as a pathogenic driver. Mechanistically, spermidine counteracts microglia lysosomal dysfunction in the brain and exerts mitochondrial antioxidant and anti-inflammatory effects in primary mouse microglia, thereby improving neuronal integrity. In the absence of Atp13a2, microglial spermidine import relies on the related polyamine transporter Atp13a3. Importantly, these findings translate to human systems, whereby spermidine attenuates inflammation in ATP13A2-deficient human differentiated microglia, while postmortem ATP13A2-deficient brain analysis confirms increased microglia reactivity. Spermidine also rescues motor deficits and dopaminergic neuron loss in ATP13A2-deficient Drosophila and other fly parkinsonism models. Together, these findings identify early polyamine dysregulation as a mechanistic contributor to ATP13A2-associated parkinsonism and nominate spermidine supplementation as a potential therapeutic strategy for ATP13A2-driven pathology and possibly a broader range of parkinsonian sub-types.
Competing Interest Statement
For the sake of transparency, it seems appropriate to declare that Pe.Va. is a scientific co-founder of EndLyz Therapeutics. The company had no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript. C. K. has served as a medical advisor to Centogene and Biogen, and received speakers honoraria from Bial and royalties from Oxford University Press and Springer Nature
Funding Statement
This research was funded by the Aligning Science Across Parkinson's [ASAP-024297] through the Michael J. Fox Foundation for Parkinson's Research (MJFF) allocated to Pe.Va., V.B., J.B. and Pa.Ve. Further support comes from the FWO research grants (G094219N and G009324N), the C1 KU Leuven research grants (C14/21/095 and C14/25/154) and the C3 KU Leuven research grant (C3/22/048) assigned to Pe.Va.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee (EC) of the University of Lubeck, Germany gave the ethics approval (number AZ07-113; Genepark) for the patient assessment (which was without postmortem). The federal state of Hamburg, Germany, approved the use of the autopsy research under the the Hamburg Hospital Act, Hamburgisches Krankenhausgesetz HmbKHG 12.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data, protocols and lab material are listed on the Key Resource Table with the respective DOI or identifiers at https:// 10.5281/zenodo.19672835. All data generated or analysed in this study can be found through the Zenodo repository at DOI: 10.5281/zenodo.19672835. All protocols are shared via protocols.io at (https://www.protocols.io/edit/cascalho-sati-et-al jwb6cparf). All data and protocols will be made publicly available as of the date of publication.
Funder Information Declared
